ALVO: Multiplikator P/S Alvotech Corp
The revenue valuation metric reflects the impact of biosimilar certification timelines and the capacity of the Icelandic plant, while 3.70 determines the current status of this parameter. Alvotech strategy relies on global distribution through alliances with major players, and the transition to mass sales of complex drugs creates leverage to offset previous R&D expenditures.
Alvotech Corp (ALVO) - rincian metrik lan laporan keuangan
- rega saham lan konsensus proyeksi valuasi:
- informasi kapitalisasi pasar:
- data ekuitas miturut neraca:
- indikator beban kredit lan likuiditas emiten:
Utang marang Modal Alvotech|ALVO - Rasio utang jangka dawa marang ekuitas|Rasio silihan jangka cendhak marang modal Alvotech Biopharmaceuticals|ALVO - Gunggung utang perusahaan|Utang-utang marang nilai buku Alvotech Corp|ALVO - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Alvotech|Rasio jangkoan perantara alvotech.com
- rincian asil keuangan lan kelipatan valuasi:
ALVO - Bathi resik|Proyeksi bathi mangsa ngarep Alvotech|ALVO - Rasio rega marang bathi|Rega marang bathi mangsa ngarep Alvotech S.A.|ALVO - Pangali rega marang bathi tumrap wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Alvotech Corp|ALVO - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben siji saham sajrone rolas wulan pungkasan Alvotech|ALVO - Bathi saben saham sajrone rolas wulan pungkasan|Dinamika bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan alvotech.com|ALVO - Wutah bathi ing taun lumaku|Dinamika bathi saben saham sing diarepake ing taun ngarep Alvotech
- indikator pendapatan dodolan lan penghasilan bisnis:
Analisis umum perusahaan:ALVO - alvotech.com
To identify fundamental benchmarks in Alvotech (ALVO) financial reporting, analyzing the market capitalization to annual revenue ratio is critical. The P/S ratio trend allows for an assessment of the risk of overpaying for the asset, reflecting the efficiency of biosimilar expansion: a decline in this metric on the chart may indicate either an undervalued business or the consequences of aggressive dumping to capture market niches.
Perusahaan pesaing
HLN (haleon.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S KVUE (Kenvue)|Multiplikator P/S Verona Pharma PLC VRNA|MENS - Rasio rega marang pendapatan|LGND: Rasio rega marang pendapatan|AMRX (Amneal Pharmaceuticals) - Kapitalisasi marang pendapatan|PRGO (perrigo.com) - Rasio rega marang pendapatan|Rasio rega marang pendapatan Liquidia|Rega marang dodolan Galapagos N.V. GLPG|Kapitalisasi marang pendapatan ANIP (ANI Pharma)|Kapitalisasi marang volume dodolan MNKD|Multiplikator P/S AMPH (Amphastar Pharmaceuticals)|pacira.com (PCRX) - Rega marang dodolan|ARS Pharmaceuticals, Inc. - Multiplikator P/S|Theravance Biopharma Inc (TBPH) - Kapitalisasi marang pendapatan|AQST: Multiplikator P/S|scPharmaceuticals - Rasio kapitalisasi pasar marang pendapatan|TECX (Tectonic Therapeutic Inc.) - Multiplikator P/S|Multiplikator P/S tonixpharma.com|Rasio rega marang pendapatan China SXT Pharmaceuticals (SXTC)|Rasio rega marang pendapatan EPRX (eupraxiapharma.com)|BioHarvest - Kapitalisasi marang pendapatan|Invizyne - Rasio rega marang pendapatan|ORMP - Rasio rega marang pendapatan|Rega marang dodolan Entera Bio Ltd.|MindWalk Holdings Inc. (HYFT) - Rasio rega marang pendapatan|Rasio rega marang dodolan ABVC (ABVC BioPharma Inc.)|CPIX (Cumberland Pharma) - Multiplikator P/S|QNTM: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S FGEN|Multiplikator P/S telomirpharma.com (TELO)|Rasio rega marang pendapatan Rani Therapeutics Holdings, Inc. RANI|Rasio kapitalisasi pasar marang pendapatan SNYR|RLYB - Rasio rega marang pendapatan|Lexaria Bioscience (LEXX) - Kapitalisasi marang pendapatan|PULM: Multiplikator P/S|Pheton Holdings (PTHL) - Multiplikator P/S|Kapitalisasi marang pendapatan APM|LYRA: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Impact BioMedical (IBO)|TNFA - Rega marang dodolan|cbdMD - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan PRFX (painreform.com)|Auris Medical - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan LIPO (Lipella Pharmaceuticals Inc)|OPTN: Multiplikator P/S|Rega marang dodolan Pieris Pharma (PIRS)|Rasio rega marang pendapatan Procaps Group S.A.|PTPI: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S QLI|Multiplikator P/S Acelyrin Inc. (SLRN)|Rasio rega marang pendapatan TFF Pharma TFFP
